American Society of Hirudotherapy

How serious a problem is bleeding in patients with acute coronary syndromes?

Review published in Current cardiology reports (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentSafety & Infection ControlSalivary PharmacologyBaber U et al. · Current cardiology reports, 2011

Abstract

Recent studies have highlighted the critical importance of bleeding complications on prognosis in patients with acute coronary syndromes (ACS). In fact, the hazard for an adverse cardiovascular event associated with bleeding is similar to that of a myocardial infarction. Several bleeding risk scores are now available that reliably quantify the probability of an ACS patient experiencing a bleeding complication. Consistent and strong correlates of bleeding include older age, female sex, renal impairment, and an invasive management approach. Although patients who tend to bleed are usually more morbid compared with their non-bleeding counterparts, several lines of experimental and clinical evidence suggest an independent and causal pathway for bleeding-associated cardiovascular risk. Given the frequency and adverse prognosis associated with bleeding, interventions that might reduce such complications are now a major emphasis in the current era of ACS treatment. Recent trials have shown that several novel antithrombotics, bivalirudin and fondaparinux, reduce bleeding risk while maintaining efficacy in reducing ischemic events during ACS. Other promising strategies that continue to be tested include the use of vascular closure devices and transradial arterial access during percutaneous coronary intervention.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAcute Coronary SyndromeAnticoagulantsFibrinolytic AgentsFondaparinuxHemorrhageHirudinsHumansIncidencePeptide FragmentsPlatelet Aggregation InhibitorsPolysaccharidesPrognosisRecombinant ProteinsRisk AssessmentRisk Factors

Summary

This review examines bleeding risk in acute coronary syndromes, noting bleeding's prognostic hazard rivals myocardial infarction, and cites trials showing bivalirudin and fondaparinux reduce bleeding while preserving efficacy, alongside radial access and closure devices.

Why This Matters for Hirudotherapy

This review article examines the prognostic significance of bleeding complications in patients with acute coronary syndromes (ACS) and discusses interventions that may reduce such risks. The abstract highlights that bleeding correlates with older age, female sex, renal impairment, and invasive management, and reports that recent trials have shown the novel antithrombotics bivalirudin and fondaparinux reduce bleeding risk while maintaining efficacy in reducing ischemic events during ACS treatment. The abstract does not mention leeches, hirudotherapy, hirudin, or the leech secretome, and provides no information about the origin or derivation of bivalirudin. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Baber U, Kovacic J, Kini AS, Sharma SK, Dangas G, Mehran R. How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep. 2011;13(4):312-319. doi:10.1007/s11886-011-0192-3. PMID: 21667168

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.